A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

计划入组 88 人 · 首次发布于 2017 年 9 月 15 日

The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)

计划入组 50 人 · 首次发布于 2019 年 11 月 5 日

The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)

计划入组 67 人 · 首次发布于 2020 年 7 月 13 日

IW-3300

IW-6118

IW-1221

Minophagen Pharmaceutical Co. Ltd.

Japan

IASO Pharma, Inc.

United States

Candel Therapeutics

United States

ImmuneWalk's IW-601 Shows Positive Phase 1 Results in Novel Monocyte-Targeting Approach for Inflammatory Diseases

ImmuneWalk Therapeutics Reports Positive Phase 1 Results for IW-601, Novel Myeloid Cell Inhibitor for Inflammatory Diseases

Corbus Pharmaceuticals Doses First Patient in Phase 1 Trial of CRB-601 for Advanced Solid Tumors